Ohtuvayre
Payments companies reported to CMS as associated with Ohtuvayre. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ohtuvayre, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ohtuvayre
These are the largest totals companies reported as associated with Ohtuvayre. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jonathan Kurman | Milwaukee, WI | Pulmonary Disease | $103,660.39 |
| Keith Harris | Port Jefferson Station, NY | Pulmonary Disease | $102,594.52 |
| Humam Farah | Hannibal, MO | Pulmonary Disease | $76,705.04 |
| Samuel Louie | Sacramento, CA | Pulmonary Disease | $44,543.28 |
| Sandeep Bansal | Du Bois, PA | Pulmonary Disease | $43,052.41 |
| Briana Disilvio | Pittsburgh, PA | Critical Care Medicine (Internal Medicine) | $25,957.11 |
| Darryle Bullard | Cullman, AL | Pulmonary Disease | $21,558.79 |
| Richard Silverman | Waterbury, CT | Critical Care Medicine (Internal Medicine) | $20,529.47 |
| Jasshan Mehrotra | Naperville, IL | Pulmonary Disease | $19,902.27 |
| Sherif El Bayadi | Syracuse, NY | Pulmonary Disease | $19,710.98 |
Prescribed Ohtuvayre?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.